All Stories

  1. Real-World Safety and Outcome of First-Line Pembrolizumab Monotherapy for Metastatic NSCLC with PDL-1 Expression ≥ 50%: A National Italian Multicentric Cohort (“PEMBROREAL” Study)

    Article • Cancers, May 2024, MDPI AG

    Dr Marco Chiumente

  2. Real World Safety and Outcome of First Line Pembrolizumab Monotherapy for Metastatic NSCLC with PDL-1 Expression ≥ 50%: A National Italian Multicentric Cohort (“PEMBROREAL” Study)

    Article • April 2024, MDPI AG

    Dr Marco Chiumente

  3. EFFICACY OF DEPRESCRIBING ON HEALTH OUTCOMES: AN UMBRELLA REVIEW OF SYSTEMATIC REVIEWS WITH META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS

    Article • Ageing Research Reviews, February 2024, Elsevier

    Dr Marco Chiumente

  4. Low-Intensity and Chemo-Free Treatments in Ph+ ALL: Progression-Free Survival Based on Indirect Comparisons

    Article • Hematology Reports, November 2023, MDPI AG

    Dr Marco Chiumente

  5. Tislelizumab plus chemotherapy vs. pembrolizumab plus chemotherapy for the first-line treatment of advanced non-small cell lung cancer: systematic review and indirect comparison of randomized trials

    Article • Chinese Clinical Oncology, October 2023, AME Publishing Company

    Dr Marco Chiumente

  6. Low-Intensity and Chemo-Free Treatments in Ph+ ALL: Progression-Free Survival Based on Indirect Comparisons

    Article • September 2023, MDPI AG

    Dr Marco Chiumente

  7. Low-Intensity and Chemo-Free Treatments in Ph+ ALL: Progression-Free Survival Based on Indirect Comparisons

    Article • July 2023, MDPI AG

    Dr Marco Chiumente

  8. Progression-Free and Overall Survival of First-Line Treatments for Advanced Renal Cell Carcinoma: Indirect Comparison of Six Combination Regimens

    Article • Cancers, March 2023, MDPI AG

    Dr Marco Chiumente

  9. Application of the IPDfromKM-Shiny Method to Compare the Efficacy of Novel Treatments Aimed at the Same Disease Condition: A Report of 14 Analyses

    Article • Cancers, March 2023, MDPI AG

    Dr Marco Chiumente

  10. Survival in Patients with Relapsed-Refractory Multiple Myeloma: Indirect Comparison of Six New Treatments

    Article • Hematology Reports, January 2023, MDPI AG

    Dr Marco Chiumente

  11. Treatments for Relapsed-Refractory Diffuse Large B-cell Lymphoma: A Preliminary Evaluation of the Place in Therapy of Glofitamab, a Bispecific Monoclonal Antibody

    Article • Cureus, December 2022, Springer Science + Business Media

    Dr Marco Chiumente

  12. Chimeric Antigen Receptor T Cells in Large B-Cell Lymphoma: Analysis of Overall Survival Based on Reconstructed Patient-Level Data

    Article • Clinical Therapeutics, December 2022, Elsevier

    Dr Marco Chiumente

  13. Survival with novel hormonal therapies in patients with nonmetastatic castration-resistant prostate cancer: indirect comparison of three randomized phase-III trials

    Article • World Journal of Urology, September 2022, Springer Science + Business Media

    Dr Marco Chiumente

  14. The “One-to-Many” Survival Analysis to Evaluate a New Treatment in Comparison With Therapeutic Alternatives Based on Reconstructed Patient Data: Enfortumab Vedotin Versus Standard of Care in Advanced or Metastatic Urothelial Carcinoma

    Article • Cureus, August 2022, Springer Science + Business Media

    Dr Marco Chiumente

  15. Immune checkpoint inhibitors as first line in advanced melanoma: Evaluating progression‐free survival based on reconstructed individual patient data

    Article • Cancer Medicine, August 2022, Wiley

    Dr Marco Chiumente

  16. First-line chemoimmunotherapy versus chemotherapy in PD-L1-negative patients with non-small-cell lung cancer

    Article • Immunotherapy, August 2022, Future Medicine

    Dr Marco Chiumente

  17. Indirect comparison of three PARP inhibitors (olaparib, niraparib, and rucaparib) as maintenance treatment in ovarian carcinoma patients responding to platinum therapy

    Article • International Journal of Clinical Pharmacology and Therapeutics, August 2022, Dustri-Verlgag Dr. Karl Feistle

    Dr Marco Chiumente

  18. Age-Adjusted Survival Extrapolations—Results May Differ From Those Generated by the Weibull Model

    Article • JAMA Cardiology, May 2022, American Medical Association (AMA)

    Dr Marco Chiumente

  19. Medical Therapy, Radiofrequency Ablation, or Cryoballoon Ablation as First-Line Treatment for Paroxysmal Atrial Fibrillation: Interpreting Efficacy Through the Shiny Method

    Article • Cureus, February 2022, Springer Science + Business Media

    Dr Marco Chiumente

  20. Adjuvant Nivolumab in Esophageal or Gastroesophageal Junction Cancer: the Improvement in Progression-Free Survival Is Small

    Article • Journal of Gastrointestinal Cancer, January 2022, Springer Science + Business Media

    Dr Marco Chiumente

  21. The Degree of Programmed Death-Ligand 1 (PD-L1) Positivity as a Determinant of Outcomes in Metastatic Triple-Negative Breast Cancer Treated With First-Line Immune Checkpoint Inhibitors

    Article • Cureus, January 2022, Springer Science + Business Media

    Dr Marco Chiumente

  22. Evaluation of maintenance treatment with PARP inhibitors in ovarian carcinoma patients responding to platinum therapy: Use of restricted mean survival time as an index of efficacy

    Article • International Journal of Clinical Pharmacology and Therapeutics, January 2022, Dustri-Verlgag Dr. Karl Feistle

    Dr Marco Chiumente

  23. A preliminary estimate of survival gain and cost-effectiveness of CAR-T in adult patients with acute lymphoblastic leukemia

    Article • Leukemia & Lymphoma, December 2021, Taylor & Francis

    Dr Marco Chiumente

  24. Pembrolizumab in Non-Small Cell Lung Cancer: The Role of Restricted Mean Survival Time in Estimating The Long-Term Survival Benefit

    Article • December 2021, sPage.direcT

    Dr Marco Chiumente

  25. Oncostability: stability of reconstituted and diluted anticancer medicines for a possible extension of use

    Article • European Journal of Hospital Pharmacy, December 2021, BMJ

    Dr Marco Chiumente

  26. The QOSMOS Study: Pharmacist-Led Multicentered Observational Study on Quality of Life in Multiple Sclerosis

    Article • Neurology International, December 2021, MDPI AG

    Dr Marco Chiumente

  27. Efficacy of Immune Checkpoint Inhibitors in Patients with Mismatch Repair-Deficient or Microsatellite Instability-High Metastatic Colorectal Cancer: Analysis of Three Phase-II Trials

    Article • Cureus, November 2021, Springer Science + Business Media

    Dr Marco Chiumente

  28. Experience in managing independent clinical research, the best training strategy for future clinical pharmacists: the QOSMOS project

    Article • European Journal of Hospital Pharmacy, June 2021, BMJ

    Dr Marco Chiumente

  29. Hospital Pharmacy Response to Covid-19 Pandemic in Italy: What We Learned From the First Outbreak Wave

    Article • Journal of Pharmacy Practice, June 2021, SAGE Publications

    Dr Marco Chiumente

  30. COVID-19 impact on skills and professional perceptions of the hospital pharmacist during the first outbreak wave

    Article • European Journal of Hospital Pharmacy, April 2021, BMJ

    Dr Marco Chiumente

  31. Preparation of intravenous chemotherapy bags: evaluation of a dose banding approach in an Italian oncology hospital

    Article • Global & Regional Health Technology Assessment, March 2021, Aboutscience Srl

    Dr Marco Chiumente

  32. SARS-COV-2 pandemic: establishing three risk levels for 19 Italian regions and two autonomous provinces

    Article • European Journal of Hospital Pharmacy, February 2021, BMJ

    Dr Marco Chiumente

  33. Restricted mean survival time as outcome measure in advanced urothelial bladder cancer: analysis of 4 clinical studies

    Article • Immunotherapy, February 2021, Future Medicine

    Dr Marco Chiumente

  34. Toward a common understanding of competencies for health technology assessment: enhancing educational and training programs around the globe

    Article • International Journal of Technology Assessment in Health Care, December 2020, Cambridge University Press

    Dr Marco Chiumente

  35. Chimeric antigen receptor T-cell (CART) therapy in non-Hodgkin’s lymphoma: the survival gain improves as more mature follow-up data become available

    Article • European Journal of Hospital Pharmacy, November 2020, BMJ

    Dr Marco Chiumente

  36. The Restricted Mean Survival Time as a Tool for Ranking Comparative Outcomes in a Narrative Review that Evaluates a Network of Randomized Trials: An Example Based on PCSK9 Inhibitors

    Article • American Journal of Cardiovascular Drugs, October 2020, Springer Science + Business Media

    Dr Marco Chiumente

  37. Omega-3 for the prevention of cardiovascular diseases: meta-analysis and trial-sequential analysis

    Article • European Journal of Hospital Pharmacy, June 2020, BMJ

    Dr Marco Chiumente

  38. Tisagenlecleucel in Non-Hodgkin Lymphoma: The Restricted Mean Survival Time as a Tool for Estimating Progression-Free Life Expectancy Better than the Median

    Article • Acta Haematologica, February 2020, Karger Publishers

    Dr Marco Chiumente

  39. CAR-T Treatment: Determining the Survival Gain in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

    Article • Clinical Lymphoma Myeloma & Leukemia, February 2020, Elsevier

    Dr Marco Chiumente

  40. Tyrosine-kinase inhibitor discontinuation in chronic myeloid leukaemia after deep molecular response: a meta-analysis with meta-regression

    Article • Journal of Chemotherapy, January 2020, Taylor & Francis

    Dr Marco Chiumente

  41. Axicabtagene ciloleucel in non-Hodgkin lymphoma: the restricted mean survival time as a tool for estimating progression-free life expectancy better than the median

    Article • Therapeutic Advances in Medical Oncology, January 2020, SAGE Publications

    Dr Marco Chiumente

  42. A Model-Independent Method to Determine Restricted Mean Survival Time in the Analysis of Survival Curves

    Article • SN Comprehensive Clinical Medicine, December 2019, Springer Science + Business Media

    Dr Marco Chiumente

  43. Analysis of Survival Curves: Statistical Methods Accounting for the Presence of Long-Term Survivors

    Article • Frontiers in Oncology, June 2019, Frontiers

    Dr Marco Chiumente

  44. Trastuzumab biosimilar in metastatic breast cancer: Evaluating equivalence with originator using network meta-analysis

    Article • International Journal of Clinical Pharmacology and Therapeutics, December 2018, Dustri-Verlgag Dr. Karl Feistle

    Dr Marco Chiumente

  45. Safety of intravitreal injections: Non-inferiority of bevacizumab compared with ranibizumab

    Article • International Journal of Clinical Pharmacology and Therapeutics, October 2018, Dustri-Verlgag Dr. Karl Feistle

    Dr Marco Chiumente

  46. Insulin Delivery Systems for Type 1 Diabetes Mellitus - A Comparison Using a Decision Analysis Modeling Approach

    Article • Value in Health, May 2018, Elsevier

    Dr Marco Chiumente

  47. Ulipristal acetate for pre-operative management of uterine fibroids: Modeling outcomes and costs

    Article • European Journal of Obstetrics & Gynecology and Reproductive Biology, March 2018, Elsevier

    Dr Marco Chiumente

  48. Optimization of resources by drug management: A multicentred web-administered study on the use of ipilimumab in Italy

    Article • Journal of Oncology Pharmacy Practice, February 2018, SAGE Publications

    Dr Marco Chiumente

  49. Promoting the use of Markovian simulation models to study outcomes of thrombectomy after acute ischemic stroke

    Article • Journal of Cardiovascular Medicine, October 2017, Wolters Kluwer Health

    Dr Marco Chiumente

  50. Burden of uterine fibroids in Italy: epidemiology, treatment outcomes, and consumption of health care resources in more than 5,000 women [Corrigendum]

    Article • ClinicoEconomics and Outcomes Research, October 2017, Dove Medical Press

    Dr Marco Chiumente, Dr Andrea Messori, Enrica maria Proli

  51. Rituximab biosimilar evaluated by network meta-analysis

    Article • Haematologica, September 2017, Ferrata Storti Foundation (Haematologica)

    Dr Marco Chiumente

  52. Rituximab biosimilar in rheumatoid arthritis: an enhanced-evidence assessment to evaluate equivalence with the originator based on network meta-analysis

    Article • Therapeutic Advances in Musculoskeletal Disease, August 2017, SAGE Publications

    Dr Andrea Messori, Dr Marco Chiumente

  53. Burden of uterine fibroids in Italy: epidemiology, treatment outcomes, and consumption of health care resources in more than 5,000 women

    Article • ClinicoEconomics and Outcomes Research, August 2017, Dove Medical Press

    Dr Marco Chiumente, Dr Andrea Messori, Enrica maria Proli

  54. Ipilimumab in real-world clinical practice: efficacy and safety data from a multicenter observational study

    Article • Journal of Chemotherapy, April 2017, Taylor & Francis

    Dr Marco Chiumente

  55. Comorbidity, Polytherapy, and Drug Interactions in a Neurological Context: An Example of a Multidisciplinary Approach to Promote the Rational Use of Drugs

    Article • Journal of Pharmacy Practice, March 2017, SAGE Publications

    Dr Marco Chiumente

  56. The Life Cycle of Health Technologies. Challenges and Ways Forward

    Article • Frontiers in Pharmacology, January 2017, Frontiers

    Dr Marco Chiumente

  57. OP127 Analysis Of The Competencies To Be Acquired In Health Technology Assessment

    Article • International Journal of Technology Assessment in Health Care, January 2017, Cambridge University Press

    Dr Marco Chiumente

  58. Differences in Effectiveness among Devices for Endovascular Thrombectomy in Patients with Acute Ischemic Stroke

    Article • Journal of Stroke, May 2016, Korean Stroke Society (KAMJE)

    Dr Marco Chiumente

  59. CAPACITY BUILDING IN AGENCIES FOR EFFICIENT AND EFFECTIVE HEALTH TECHNOLOGY ASSESSMENT

    Article • International Journal of Technology Assessment in Health Care, January 2016, Cambridge University Press

    Dr Marco Chiumente

  60. Burden of Stroke in Italy: An Economic Model Highlights Savings Arising from Reduced Disability following Thrombolysis

    Article • International Journal of Stroke, April 2015, SAGE Publications

    Dr Marco Chiumente

  61. Economic impact of antifungal treatment in IFD byCandidaspecies: anidulafungin administration as a cost-effective alternative for critical care patients

    Article • European Journal of Hospital Pharmacy, June 2014, BMJ

    Dr Marco Chiumente

  62. CP-037 Thrombolysis performed within three hours following stroke reduces disability and costs: an economic model to estimate savings

    Article • European Journal of Hospital Pharmacy, February 2014, BMJ

    Dr Marco Chiumente

  63. OHP-026 Economic Evaluation of Antifungal Drugs in an Intensive Care Unit

    Article • European Journal of Hospital Pharmacy, March 2013, BMJ

    Dr Marco Chiumente

  64. CPC-079 Management of Myelodisplastic Syndromes and Lymphomas: The Example of Lenalidomide

    Article • European Journal of Hospital Pharmacy, March 2013, BMJ

    Dr Marco Chiumente